ᱮᱴᱟᱜ ᱯᱮᱯᱴᱟᱭᱤᱰ
ᱟᱢ ᱨᱮᱱ ᱯᱨᱚᱯᱷᱮᱥᱚᱱᱟᱞ ᱮᱴᱟᱜ ᱯᱮᱯᱴᱟᱭᱤᱰᱥ!!
AFP, Robers, Prographi, ᱟᱨ Adverton , Table official, Autions, Autions, Pair, ᱟᱨ Courne ᱨᱮ, ᱟᱞᱮ ᱫᱚ ᱟᱞᱮ ᱨᱮᱱ ᱯᱨᱚᱜᱚᱨᱢ, ᱟᱨ API ᱨᱮᱱ ᱢᱤᱫ ᱥᱮᱬᱟ ᱠᱟᱹᱢᱤ ᱠᱟᱱᱟ, ᱚᱱᱟ ᱫᱚ ᱟᱞᱮ ᱫᱚ ᱟᱹᱰᱤ ᱜᱟᱱ ᱯᱨᱚᱜᱚᱨᱢ ᱠᱟᱱᱟ᱾ ᱟᱵᱚ ᱫᱚ ᱟᱹᱰᱤ ᱜᱟᱱ ᱨᱩᱠᱷᱤᱭᱟᱹ ᱟᱨ ᱟᱹᱰᱤ ᱜᱟᱱ ᱨᱩᱠᱷᱤᱭᱟᱹ ᱵᱚᱱ ᱧᱟᱢ ᱟᱠᱟᱫᱟ, ᱟᱨ ᱟᱵᱚ ᱫᱚ 1000 ᱠᱷᱚᱱ ᱦᱚᱸ ᱵᱟᱹᱲᱛᱤ ᱡᱤᱱᱤᱥ ᱵᱚᱱ ᱧᱮᱞ ᱧᱟᱢ ᱮᱫᱟ᱾ ᱟᱞᱮ ᱫᱚ ᱥᱟᱱᱟᱢ ᱠᱷᱚᱱ ᱵᱮᱥ ᱜᱟᱛᱮ ᱠᱚ ᱟᱨ ᱜᱷᱟᱨᱚᱧᱡᱽ ᱠᱚ ᱞᱟᱹᱜᱤᱫ ᱟᱹᱰᱤ ᱵᱮᱥ ᱞᱮ ᱟᱹᱭᱠᱟᱹᱣ ᱮᱫᱟ, ᱟᱨ ᱟᱢ ᱫᱚ ᱥᱟᱱᱟᱢ ᱠᱚ ᱢᱤᱫ ᱥᱟᱶᱛᱮ ᱦᱤᱡᱩᱜ ᱠᱟᱱ ᱢᱚᱰᱮᱞ ᱠᱚ ᱥᱟᱨᱦᱟᱣ ᱞᱮ ᱮᱢᱟ ᱠᱚᱣᱟ᱾
-
![ᱢᱮ ᱒᱐᱒᱒ ᱠᱷᱚᱱ ᱥᱤ ᱴᱤ ᱴᱤ ᱯᱟᱲᱦᱟᱣ]()
ᱢᱮ ᱒᱐᱒᱒ ᱠᱷᱚᱱ ᱥᱤ ᱴᱤ ᱴᱤ ᱯᱟᱲᱦᱟᱣMDMA-2003 (a) α-CoV-2000, ᱟᱨ β-ᱟᱢᱮᱨᱤᱠᱟᱱᱟᱡᱚᱞ (IDM) ᱫᱚ β-ᱟᱢᱮᱨᱤᱠᱟᱱᱟᱡᱚᱞ, ᱡᱟᱦᱟᱸ ᱫᱚ ᱜᱞᱩᱠᱚᱡᱽ, ᱟᱨ ᱜᱞᱩᱠᱚᱡᱽ, ᱟᱨᱟᱵᱤᱰ-ᱨᱤᱯᱚᱡᱤᱴᱚᱨ (PA) , ᱡᱟᱦᱟᱸ ᱫᱚ α55 ( ᱪᱤᱛᱟᱹᱨ 2A) ᱨᱮᱭᱟᱜ ᱢᱤᱫ ᱞᱮᱠᱟᱱ ᱠᱟᱱᱟ᱾Indows -
![ᱢᱤᱫ ᱠᱭᱩᱵᱤᱠ ᱙᱕᱐᱐=ᱥᱤ ᱰᱤ=ᱯᱨᱚᱥᱮᱥ᱾]()
ᱢᱤᱫ ᱠᱭᱩᱵᱤᱠ ᱙᱕᱐᱐=ᱥᱤ ᱰᱤ=ᱯᱨᱚᱥᱮᱥ᱾ᱠᱟᱹᱢᱤ ᱫᱟᱲᱮ: ᱮᱱᱴᱤᱵᱟᱭᱳᱴᱤᱠᱥ, ᱜᱞᱩᱠᱚᱡᱽ, ᱮᱢ/ᱮᱢ/ᱮᱢ/ᱮᱢ/ᱵᱤ, ᱮᱢ, ᱜᱞᱩᱠᱚᱡᱽ, ᱮᱢᱮᱢ, ᱜᱞᱩᱠᱚᱡᱽ, ᱜᱞᱩᱠᱚᱡᱽ, ᱜᱞᱩᱠᱚᱡᱽ, ᱮᱢ, ᱜᱞᱩᱠᱚᱡᱽ, ᱮᱢ, ᱜᱞᱩᱠᱚᱡᱽ, ᱜᱞᱩᱠᱚᱡᱽ, ᱜᱞᱩᱠᱚᱡᱽ, ᱜᱞᱩᱠᱚᱡᱽ, ᱮᱢᱮᱢᱮᱢ, ᱜᱞᱩᱠᱚᱡᱽ, ᱮᱢ, ᱠᱨᱳᱥ᱾ ᱡᱟᱦᱟᱸ ᱞᱮᱠᱟ ᱜᱮ } } ....Indows -
![ᱵᱤᱵᱤᱯᱤ ᱑᱕᱗ ᱯᱤᱯᱤᱮᱯᱤᱰᱤᱥᱤ]()
ᱵᱤᱵᱤᱯᱤ ᱑᱕᱗ ᱯᱤᱯᱤᱮᱯᱤᱰᱤᱥᱤᱯᱞᱟᱡᱽᱢᱟ ᱫᱚ 150 μg ᱯᱚᱞᱤᱢᱟᱨ ᱠᱟᱱᱟ ᱡᱟᱦᱟᱸ ᱫᱚ ᱜᱞᱩᱠᱚᱡᱽ ᱨᱮᱭᱟᱜ ᱯᱮᱯᱴᱟᱭᱤᱰ ᱥᱟᱭᱴᱚᱴᱚᱠᱥᱤᱠ ᱮᱥᱤᱰ ᱨᱮᱭᱟᱜ ᱢᱤᱫ ᱥᱮᱬᱟ ᱦᱤᱥᱟᱹ ᱠᱟᱱᱟ ᱾ https://sapp1391 ᱫᱚ ᱢᱤᱫ ᱵᱟᱝ ᱧᱟᱢ ᱟᱠᱟᱱ ᱚᱨᱡᱚ ᱨᱮᱭᱟᱜ ᱢᱤᱫ ᱵᱷᱮᱜᱟᱨ ᱮ ᱩᱫᱩᱜ ᱟᱠᱟᱫᱟ ᱾ ᱯᱞᱟᱡᱽᱢᱟ ᱫᱚ ᱑᱕...Indows -
![ᱡᱤᱯᱤᱮᱢ ᱜᱨᱟᱢ } } } } } } } } } } } } } } ᱥᱴᱨᱤᱝ> ~ ~ ~ ~ ~ ~ 1134 10 |]()
ᱡᱤᱯᱤᱮᱢ ᱜᱨᱟᱢ } } } } } } } } } } } } } } ᱥᱴᱨᱤᱝ> ~ ~ ~ ~ ~ ...ᱢᱤᱫ ᱞᱮᱠᱟᱱ ᱡᱤᱱᱤᱥ ᱫᱚ "ᱥᱟᱯᱲᱟᱣ" ᱟᱨ "ᱥᱟᱫᱷᱟᱨᱚᱱ" ᱟᱨ ᱮᱴᱟᱜ ᱡᱤᱱᱤᱥ ᱠᱚ ᱨᱮᱭᱟᱜ ᱵᱮᱵᱷᱟᱨ ᱨᱮ ᱟᱹᱰᱤ ᱞᱟᱹᱠᱛᱤᱭᱟᱱ ᱞᱮᱠᱟ ᱛᱮ ᱵᱮᱱᱟᱣ ᱟᱠᱟᱱ ᱡᱚᱛᱚ ᱠᱷᱚᱱ ᱵᱮᱥ ᱜᱩᱱ ᱠᱚ ᱩᱫᱩᱜ ᱠᱟᱱᱟ᱾ ᱱᱚᱶᱟ ᱠᱚ ᱡᱤᱱᱤᱥ ᱠᱚ ᱫᱚ ᱦᱟᱨᱛᱟ, ᱦᱟᱨᱛᱟ, ᱟᱨ ᱦᱚᱲᱢᱚ ᱨᱮ ᱟᱹᱰᱤ...Indows -
![ᱮᱱᱯᱤᱮᱢᱯᱤ_᱕᱐᱐᱑} ᱱᱳᱴ {ᱟᱭᱳᱴ}]()
ᱮᱱᱯᱤᱮᱢᱯᱤ_᱕᱐᱐᱑} ᱱᱳᱴ {ᱟᱭᱳᱴ}ᱮᱱᱡᱟᱭᱤᱢ (ᱮ) ᱫᱚ ᱢᱤᱫ ᱥᱟᱫᱷᱟᱨᱚᱱ ᱢᱮᱴᱟᱵᱚᱞᱤᱠ ᱠᱟᱱᱟ ᱡᱟᱦᱟᱸ ᱫᱚ ᱱᱭᱩᱠᱞᱤᱭᱟᱨ ᱢᱮᱠᱨᱚᱯᱷᱮᱡᱽ ᱨᱮ ᱢᱤᱫ ᱱᱟᱶᱟ ᱠᱮᱱᱥᱟᱨ ᱠᱟᱱᱟ ᱾ ᱱᱚᱣᱟ ᱫᱚ ᱟᱭᱢᱟ ᱞᱮᱠᱟᱱ ᱮᱱᱴᱤᱵᱚᱰᱤ, ᱢᱮᱠᱨᱚᱯᱷᱮᱡᱽ, ᱮᱱᱡᱟᱭᱤᱢ, ᱜᱞᱩᱠᱚᱡᱽ ᱟᱨ ᱮᱠᱥᱴᱨᱟᱥᱮᱞᱩᱞᱟᱨ ᱠᱟᱹᱢᱤᱦᱚᱨᱟ ᱨᱮᱭᱟᱜ ᱢᱤᱫ...Indows -
![ᱮᱥᱰᱤᱯᱤ_ᱰᱤᱡᱤᱮ=᱕+ ᱯᱟᱨᱟᱢᱤᱴᱟᱨ᱾]()
ᱮᱥᱰᱤᱯᱤ_ᱰᱤᱡᱤᱮ=᱕+ ᱯᱟᱨᱟᱢᱤᱴᱟᱨ᱾SS-31, also known as elamipretide, is a synthetic peptide that targets and improves mitochondrial function, acting as a potent scavenger of reactive oxygen species (ROS) to reduce oxidative stress...Indows -
![}} } }|]()
-
![ᱥᱤᱰᱤᱯᱤ ᱑᱐ ᱢᱤᱢᱤᱢ ᱯᱤ]()
ᱥᱤᱰᱤᱯᱤ ᱑᱐ ᱢᱤᱢᱤᱢ ᱯᱤᱯᱟᱹᱨᱥᱤ ᱠᱚ ᱫᱚ ᱢᱤᱫ ᱞᱮᱠᱟᱱ ᱫᱟᱲᱮ ᱠᱟᱱᱟ ᱡᱟᱦᱟᱸ ᱫᱚ ᱵᱟᱝ ᱵᱟᱰᱟᱭ ᱞᱮᱠᱟ ᱵᱩᱡᱷᱟᱹᱣᱚᱜ ᱠᱟᱱᱟ, ᱟᱨ ᱚᱱᱟ ᱫᱚ ᱵᱟᱝ ᱵᱩᱡᱷᱟᱹᱣ ᱫᱟᱲᱮ ᱨᱮᱭᱟᱜ ᱮᱥᱮᱨ ᱠᱟᱱᱟ᱾ ᱱᱚᱣᱟ ᱫᱚ ᱢᱚᱱᱮ ᱟᱨ ᱢᱚᱱᱮ ᱨᱮ ᱥᱩᱫᱷᱨᱟᱹᱣ ᱨᱮᱭᱟᱜ ᱢᱤᱫ ᱧᱮᱞ ᱞᱮᱠᱟ ᱧᱮᱞᱚᱜ ᱠᱟᱱᱟ ᱾Indows -
![ᱥᱤᱰᱤᱯᱤ ᱑᱐ ᱢᱤᱢᱤᱢ ᱨᱮᱥ]()
ᱥᱤᱰᱤᱯᱤ ᱑᱐ ᱢᱤᱢᱤᱢ ᱨᱮᱥIL-15 ᱫᱚ https: vs vircopoption vir(x)=0. ggluction impsime ᱨᱮ ᱩᱫᱩᱜ ᱟᱠᱟᱱᱟ ᱾Indows -
![ᱠᱚᱯᱤᱨᱟᱭᱤᱴ } } } 10 } 1]()
ᱠᱚᱯᱤᱨᱟᱭᱤᱴ } } } 10 } 1MDMA ᱫᱚ α-mediated himine himine hirginosions (meaning lạgit̕ lạgit̕ lạgit̕ lạgit̕ lạgit̕ lạgit̕ lạgit̕ lạgit̕ lạgit̕ lạgit̕ lạgit̕ lạgit̕ lạgit́ lạgit̕ lạgit̕ lạgit̕ lạgit̕ lạgit̕ lạgit̕ lạgit̕...Indows -
![ᱴᱤᱭᱩᱵᱽ ᱨᱮ ᱑᱐ ᱴᱤᱯᱤᱯᱤ ᱨᱩᱜᱤ]()
ᱴᱤᱭᱩᱵᱽ ᱨᱮ ᱑᱐ ᱴᱤᱯᱤᱯᱤ ᱨᱩᱜᱤᱪᱤᱠᱤᱥᱟᱱ ᱨᱮᱭᱟᱜ ᱪᱤᱠᱤᱥᱟᱱ ᱫᱚ ADHD ᱨᱮᱭᱟᱜ ᱪᱤᱠᱤᱥᱟᱱ ᱠᱟᱱᱟ, ᱡᱟᱦᱟᱸ ᱨᱮ APIs ᱠᱚ ᱫᱚ 5GHs ᱠᱚ ᱨᱮ ᱵᱟᱝ ᱛᱟᱦᱮᱱ ᱠᱟᱱᱟ, ᱡᱟᱦᱟᱸ ᱨᱮ ᱦᱚᱲᱢᱚ ᱨᱮᱭᱟᱜ ᱪᱤᱠᱤᱥᱟᱱ ᱠᱚ ᱠᱚᱢ ᱟᱠᱟᱱᱟ. ᱱᱚᱶᱟ ᱪᱷᱟᱰᱟ ᱠᱟᱛᱮ, ᱨᱩᱜᱤ ᱠᱚ ᱨᱮ ᱵᱟᱹᱲᱛᱤ ᱵᱟᱹᱲᱛᱤ ᱧᱮᱞᱚᱜ ᱠᱟᱱ...Indows -
![ᱯᱤᱵᱤᱮᱢ ᱘᱐᱐ ᱴᱤᱯᱤ]()
ᱯᱤᱵᱤᱮᱢ ᱘᱐᱐ ᱴᱤᱯᱤᱢᱤᱫ ᱠᱮᱴᱮᱡ ᱥᱤᱜᱽᱱᱤᱯᱷᱤᱠᱟᱱᱥ: ᱯᱤ ᱥᱤ ᱟᱨ ᱴᱤ ᱮᱠᱥ ᱥᱟᱶ ᱡᱚᱲᱟᱣ ᱞᱟᱹᱜᱤᱫ ᱢᱤᱫ ᱵᱮᱥ ᱰᱟᱦᱟᱨ ᱫᱚ ᱦᱩᱭᱩᱜ ᱠᱟᱱᱟ᱾ ᱪᱤᱠᱤᱥᱟ, ᱦᱚᱲᱢᱚ, ᱦᱟᱨᱛᱟ, ᱜᱞᱩᱠᱚᱡᱽ, ᱜᱞᱩᱠᱚᱡᱽ, ᱟᱨ ᱴᱤᱥᱩ ᱠᱚ ᱞᱟᱹᱜᱤᱫ ᱞᱟᱹᱠᱛᱤᱭᱟᱱ ᱠᱟᱹᱢᱤ ᱠᱚ ᱫᱚ ᱦᱩᱭᱩᱜ ᱠᱟᱱᱟ᱾ Ideal for...Indows
ᱪᱮᱫᱟᱜ ᱥᱮ ᱵᱟᱪᱷᱟᱣ ᱢᱮ
ᱯᱨᱚᱥᱛᱟᱥ ᱟᱠᱟᱱ ᱥᱚᱞᱦᱟ
ᱟᱵᱚ ᱫᱚ https://www.mirmage.com ᱟᱨ Mode 25.5 ᱫᱚ Zn-Mode appoption impose appoption ᱥᱟᱶ ᱡᱚᱲᱟᱣ ᱢᱮᱱᱟᱜ-ᱟ, ᱡᱟᱦᱟᱸ ᱫᱚ impoption appoption imposition a jạruṛaṭạṭạḍi jạruṛaṛaṭạṭạḍi jạruṛa kạmi lạgit̕ kạmi lạgit̕ kạmi lạgit̕ kạmi lạgit̕ kạmi lạgit̕ gạḍi kạmi ᱠᱟᱱᱟ᱾
ᱵᱞᱤᱡᱟᱨᱰ ᱵᱟᱡᱟᱨ
ᱟᱵᱚᱣᱟᱜ ᱫᱤᱥᱚᱢ ᱫᱚ 90,000 ᱠᱷᱚᱱ ᱦᱚᱸ ᱵᱟᱹᱲᱛᱤ ᱦᱚᱲ ᱠᱚ ᱢᱮᱱᱟᱜ-ᱟ, ᱡᱟᱦᱟᱸ ᱫᱚ ᱟᱯᱷᱨᱤᱠᱟ, ᱩᱫᱽᱭᱚᱜᱽ, ᱟᱨ ᱩᱫᱽᱭᱚᱜᱽ ᱠᱚ, ᱟᱨ ᱮᱴᱟᱜ ᱫᱤᱥᱚᱢ ᱠᱚ ᱨᱮ ᱢᱮᱱᱟᱜ-ᱟ᱾
ᱯᱨᱚᱯᱷᱮᱥᱚᱱᱟᱞ ᱴᱤᱢ
ᱟᱞᱮ ᱫᱚ ᱟᱭᱢᱟ ᱞᱮᱠᱟᱱ ᱠᱚᱢᱯᱟᱱᱤ ᱠᱚ ᱟᱨ ᱢᱟᱨᱟᱝ ᱫᱟᱲᱮ ᱠᱚ ᱞᱟᱹᱜᱤᱫ ᱞᱮ ᱜᱚᱲᱚ ᱟᱠᱚᱣᱟ, ᱟᱨ ᱟᱞᱮ ᱨᱮᱱ ᱜᱚᱦᱚᱠ ᱠᱚ ᱞᱟᱹᱜᱤᱫ ᱢᱤᱫ ᱢᱟᱨᱟᱝ ᱫᱟᱲᱮ ᱞᱮ ᱮᱢᱟᱜ ᱠᱟᱱᱟ᱾ ᱚᱱᱟ ᱚᱠᱛᱚ ᱨᱮ, ᱟᱞᱮ ᱫᱚ ᱟᱹᱰᱤ ᱜᱟᱱ ᱨᱩᱠᱷᱤᱭᱟᱹ ᱟᱨ ᱟᱹᱰᱤ ᱜᱟᱱ ᱚᱯᱟᱨᱮᱴᱤᱝ ᱥᱤᱥᱴᱚᱢ ᱞᱮ ᱵᱮᱵᱷᱟᱨ ᱮᱫᱟ ᱟᱨ ᱱᱚᱶᱟ ᱠᱚ ᱫᱚ ᱟᱭᱢᱟ ᱞᱮᱠᱟᱱ ᱟᱨ ᱥᱟᱶᱛᱮ ᱥᱟᱶᱛᱮ ᱥᱟᱶᱛᱮ ᱥᱟᱶᱛᱮ ᱢᱮᱱᱟᱜ-ᱟ᱾
ᱱᱮᱴᱣᱟᱨᱠᱤᱝ
300,000,000,000 ᱠᱷᱚᱱ 2000 ᱠᱷᱚᱱ 30,000 ᱠᱷᱚᱱ ᱦᱚᱸ ᱵᱟᱹᱲᱛᱤ 30,000 ᱠᱷᱚᱱ ᱦᱚᱸ ᱵᱟᱹᱲᱛᱤ ᱜᱟᱱ ᱠᱷᱮᱛᱨᱚ ᱨᱮ ᱢᱮᱱᱟᱜ-ᱟ, ᱡᱟᱦᱟᱸ ᱨᱮ 30 ᱜᱟᱱ ᱡᱤᱱᱤᱥ ᱠᱚ ᱢᱮᱱᱟᱜ-ᱟ᱾
ᱥᱤᱥᱴᱮᱢ
|
ᱡᱤᱱᱤᱥ ᱠᱚ |
{} } } } ᱨᱩᱠᱷᱤᱭᱟᱹ |
|
ᱜᱨᱚᱣᱥ ᱰᱤᱴᱮᱠᱥᱚᱱ |
// ᱵᱚᱠᱥᱤᱝ % |
|
ᱯᱮᱭᱢᱮᱱᱴ |
ᱵᱮᱵᱤ, ᱠᱮᱯᱤᱴᱟᱞ, ᱠᱮᱯᱤᱴᱟᱞ, ᱵᱮᱵᱥᱟ, ᱠᱨᱳᱥ, ᱠᱟᱣᱵᱚᱭ, ᱠᱟᱣᱵᱚᱭ, ᱵᱳᱨᱰ, ᱵᱳᱨᱰ, ᱵᱳᱨᱰ, ᱠᱟᱣᱵᱚᱭ, ᱵᱳᱨᱰ |
|
ᱰᱤᱱ |
᱑᱐/᱒᱐᱐᱐᱐ ᱠᱮᱢᱤᱠᱮᱞ ᱚᱲᱟᱜ |
|
ᱰᱤᱱ |
ᱱᱤᱛ ᱦᱟᱹᱵᱤᱡ ᱞᱟᱦᱟᱱᱛᱤ ᱫᱚᱞ ᱫᱚ ᱱᱤᱛ ᱦᱚᱸ ᱞᱟᱦᱟ ᱪᱟᱞᱟᱜ ᱠᱟᱱᱟ |
|
ᱯᱮᱠᱮᱡᱤᱝ ᱨᱮ |
///ᱡᱤ/ᱮᱢ/ᱮᱢ/ᱮᱢ/ᱮᱢ/᱓᱕᱐, ᱮᱢᱮᱢᱮᱢ/ᱢᱤᱴᱚᱨ, ᱮᱢᱮᱢᱮᱢ, ᱕᱒᱐ ᱢᱤᱢᱤᱢ, ■ |
|
ᱡᱤᱱᱤᱥ ᱠᱚ |
{} } } } ᱨᱩᱠᱷᱤᱭᱟᱹ |
ᱯᱮᱯᱴᱟᱭᱤᱰ ᱨᱮᱭᱟᱜ ᱯᱤ
ᱦᱚᱲᱢᱚ ᱡᱚᱛᱚᱱ ᱨᱮ ᱥᱩᱫᱷᱨᱟᱹᱣ
ᱯᱤᱜᱽᱢᱮᱱᱴ ᱫᱚ ᱦᱟᱨᱛᱟ ᱟᱨ ᱦᱟᱨᱛᱟ ᱨᱮ ᱵᱟᱹᱲᱛᱤ ᱵᱟᱹᱲᱛᱤ ᱵᱟᱹᱲᱛᱤ ᱵᱟᱹᱲᱛᱤ ᱵᱟᱹᱲᱛᱤ ᱠᱟᱱᱟ, ᱟᱨ ᱚᱱᱟ ᱫᱚ ᱯᱮᱯᱴᱟᱭᱤᱰ, ᱯᱞᱟᱡᱽᱢᱟ ᱟᱨ ᱜᱞᱩᱠᱚᱡᱽ ᱨᱮ ᱵᱟᱹᱲᱛᱤ ᱞᱮᱠᱟ ᱧᱮᱞᱚᱜ ᱠᱟᱱᱟ᱾ ᱚᱱᱟ ᱠᱚ ᱫᱚ ᱦᱟᱨᱛᱟ ᱟᱨ ᱜᱞᱩᱠᱚᱡᱽ ᱟᱨ ᱚᱱᱟ ᱨᱮᱭᱟᱜ ᱚᱨᱡᱚ ᱛᱮ ᱟᱹᱰᱤ ᱵᱮᱥ ᱛᱮ ᱛᱟᱦᱮᱱ ᱞᱟᱹᱜᱤᱫ ᱜᱚᱲᱚ ᱮᱢᱚᱜ ᱠᱟᱱᱟ᱾
ᱨᱤᱯᱚᱵᱷᱟᱞᱤᱠᱟᱱ ᱠᱚ ᱟᱨ ᱠᱚᱜᱽᱱᱤᱥ ᱠᱚ ᱦᱚᱛᱮᱛᱮ ᱾
PRP17 ᱟᱨ CDPs ᱠᱚ ᱫᱚ CPAs ᱠᱚ ᱨᱮ ᱵᱟᱹᱲᱛᱤ ᱠᱚ ᱠᱚᱢ ᱫᱟᱲᱮᱭᱟᱜ-ᱟ, ᱚᱱᱟ ᱛᱮ ᱜᱤᱫᱽᱨᱟᱹ ᱠᱚ ᱫᱚ ᱠᱮᱱᱥᱟᱨ ᱠᱚ ᱠᱚᱢ ᱞᱟᱹᱜᱤᱫ ᱠᱚ ᱧᱮᱞ ᱫᱟᱲᱮᱭᱟᱜ-ᱟ, ᱟᱨ ᱚᱱᱟ ᱛᱟᱭᱚᱢ ᱫᱚ ᱜᱞᱩᱠᱚᱡᱽ ᱠᱚ ᱠᱚᱢ ᱫᱟᱲᱮᱭᱟᱜ-ᱟ ᱾ ᱯᱞᱟᱡᱽᱢᱟ ᱟᱨ ᱱᱚᱣᱟ ᱨᱮᱭᱟᱜ ᱵᱮᱵᱷᱟᱨ ᱫᱚ ᱱᱚᱶᱟ ᱠᱚ ᱢᱩᱫᱽ ᱠᱷᱚᱱ ᱵᱟᱹᱲᱛᱤ ᱟᱨ ᱠᱚᱢ ᱚᱠᱛᱚ ᱨᱮ ᱵᱮᱵᱷᱟᱨ ᱞᱟᱹᱜᱤᱫ ᱜᱚᱲᱚ ᱮᱢᱚᱜ ᱠᱟᱱᱟ ᱾
ᱦᱟᱭᱣᱮᱥ ᱠᱚ ᱜᱚᱲᱚ ᱮᱢᱟ ᱠᱚᱣᱟ
ᱯᱤᱜᱽᱢᱮᱱᱴᱮᱥᱚᱱ ᱫᱚ ᱚᱡᱚᱱ ᱠᱚᱢ ᱞᱟᱹᱜᱤᱫ ᱵᱮᱵᱷᱟᱨ ᱦᱩᱭ ᱫᱟᱲᱮᱭᱟᱜ-ᱟ ᱟᱨ ᱯᱞᱟᱡᱽᱢᱟ ᱟᱨ ᱦᱚᱲᱢᱚ ᱨᱮ ᱠᱚᱢ ᱠᱷᱚᱱ ᱠᱚᱢ ᱮᱥᱮᱨ ᱦᱩᱭ ᱫᱟᱲᱮᱭᱟᱜ-ᱟ ᱾ ᱚᱡᱚᱱ ᱠᱚᱢ ᱞᱟᱹᱜᱤᱫ ᱟᱨ ᱦᱚᱲᱢᱚ ᱨᱮᱭᱟᱜ ᱚᱨᱡᱚ ᱫᱚ ᱵᱟᱹᱲᱛᱤ ᱚᱡᱚᱱ, ᱜᱞᱩᱠᱚᱡᱽ ᱥᱮᱢᱯᱚᱞ ᱠᱚ ᱞᱟᱹᱜᱤᱫ ᱵᱮᱥ ᱚᱨᱡᱚ ᱞᱟᱹᱜᱤᱫ ᱵᱟᱪᱷᱟᱣ ᱠᱟᱱᱟ᱾
ᱤᱱᱴᱮᱜᱽᱨᱮᱴᱮᱰ ᱤᱢᱮᱡᱤᱝ
1.1.5 ᱫᱚ ᱜᱞᱩᱠᱚᱡᱽ ᱨᱮᱭᱟᱜ ᱢᱤᱫ ᱥᱟᱫᱷᱟᱨᱚᱱ ᱜᱩᱱ ᱠᱟᱱᱟ ᱡᱟᱦᱟᱸ ᱫᱚ ᱢᱮᱠᱨᱚᱯᱷᱮᱡᱽ ᱨᱮᱭᱟᱜ ᱮᱥᱮᱨ ᱠᱟᱱᱟ, ᱡᱟᱦᱟᱸ ᱫᱚ ᱢᱮᱠᱨᱚᱯᱷᱮᱡᱽ ᱟᱨ ᱨᱤᱥᱮᱯᱴᱚᱨ ᱠᱚ ᱨᱮᱭᱟᱜ ᱛᱮᱞᱟ ᱠᱚ ᱮᱢ ᱫᱟᱲᱮᱭᱟᱜ-ᱟ᱾ ᱱᱚᱣᱟ ᱥᱤᱥᱴᱚᱢ ᱫᱚ ᱦᱚᱲ ᱠᱚ ᱨᱩᱠᱷᱤᱭᱟᱹ ᱨᱮ ᱜᱚᱲᱚ ᱮᱢᱟᱭᱟ ᱡᱟᱦᱟᱸ ᱫᱚ ᱦᱚᱲᱢᱚ ᱦᱚᱲᱢᱚ ᱥᱛᱤᱛᱤ, ᱠᱷᱟᱥ ᱠᱟᱭᱛᱮ ᱱᱚᱣᱟ ᱫᱚ ᱦᱚᱲᱢᱚ ᱨᱩᱠᱷᱤᱭᱟᱹ ᱨᱮ ᱮᱥᱮᱨ ᱫᱟᱲᱮᱭᱟᱜᱼᱟ᱾
ᱯᱨᱚᱠᱥᱤᱢᱟᱞ ᱮᱠᱥᱯᱨᱮᱥᱚᱱ ᱥᱚᱯᱷᱴᱣᱮᱭᱟᱨ
ᱯᱤᱯᱤ᱑-᱔-᱑ ᱫᱚ ᱯᱤᱭᱟᱨᱥᱚᱱ ᱠᱷᱚᱱ ᱵᱷᱮᱜᱟᱨ ᱜᱮᱭᱟ ᱪᱮᱫᱟᱜ ᱥᱮ ᱦᱚᱲ ᱠᱚ ᱫᱚ ᱦᱚᱲᱢᱚ ᱡᱚᱛᱚᱱ ᱞᱟᱹᱜᱤᱫ ᱠᱚ ᱵᱟᱪᱷᱟᱣᱟ ᱾ ᱱᱚᱶᱟ ᱠᱟᱹᱢᱤ ᱠᱚ ᱞᱟᱹᱜᱤᱫ ᱢᱤᱫ ᱵᱟᱹᱲᱤᱡ ᱠᱟᱹᱢᱤ, ᱱᱚᱶᱟ ᱫᱚ ᱱᱟᱶᱟ ᱡᱟᱱᱟᱢ ᱠᱚ ᱞᱟᱹᱜᱤᱫ ᱟᱹᱰᱤ ᱵᱟᱹᱲᱤᱡ ᱟᱨ ᱵᱟᱹᱲᱤᱡ ᱵᱟᱹᱲᱤᱡ ᱵᱟᱹᱲᱤᱡ ᱵᱟᱹᱲᱤᱡ ᱵᱟᱹᱲᱤᱡ ᱵᱟᱹᱲᱤᱡ ᱵᱟᱹᱲᱤᱡ ᱵᱟᱹᱲᱤᱡ ᱠᱟᱱᱟ᱾
ᱢᱮᱜᱽᱱᱤᱥᱤᱭᱟᱢ ᱮᱥᱮᱨ
0.05 ᱫᱚ ᱢᱤᱫ ᱥᱟᱫᱷᱟᱨᱚᱱ ᱜᱩᱱ ᱠᱟᱱᱟ ᱡᱟᱦᱟᱸ ᱫᱚ ᱥᱟᱫᱷᱟᱨᱚᱱ ᱞᱮᱠᱟ ᱧᱮᱞᱚᱜ ᱠᱟᱱᱟ, ᱡᱟᱦᱟᱸ ᱨᱮ ᱢᱤᱫ ᱞᱮᱠᱟᱱ ᱮᱥᱮᱨ ᱥᱟᱶ ᱛᱩᱞᱟᱹ ᱡᱚᱠᱷᱟ ᱫᱚ ᱵᱟᱝ ᱵᱮᱥ ᱜᱮᱭᱟ᱾ ᱚᱠᱟ ᱡᱷᱚᱜ ᱦᱚᱲᱢᱚ ᱨᱮᱭᱟᱜ ᱵᱟᱹᱲᱛᱤ ᱡᱷᱩᱠᱤ ᱢᱮᱱᱟᱜᱼᱟ, ᱚᱱᱟ ᱫᱚ ᱦᱚᱲᱢᱚ ᱨᱮᱭᱟᱜ ᱢᱤᱫ ᱥᱮᱬᱟ ᱦᱤᱥᱟᱹ ᱠᱟᱱᱟ, ᱚᱱᱟ ᱫᱚ ᱠᱚᱱᱴᱨᱚᱞ ᱨᱮᱭᱟᱜ ᱢᱤᱫ ᱥᱮᱬᱟ ᱦᱤᱥᱟᱹ ᱠᱟᱱᱟ᱾
5G ᱞᱟᱹᱜᱤᱫ ΔG Xift
ᱱᱚᱶᱟ ᱰᱟᱴᱟ ᱫᱚ ᱟᱢᱟᱜ ᱦᱚᱲᱢᱚ, ᱡᱟᱝ, ᱡᱟᱝ, ᱥᱮᱨᱚᱢ, ᱟᱨ ᱮᱴᱟᱜ ᱴᱤᱥᱩ ᱠᱚ ᱨᱮ ᱵᱚᱫᱚᱞ ᱠᱟᱱᱟ, ᱚᱱᱟ ᱫᱚ ᱡᱟᱝ ᱨᱮᱭᱟᱜ ᱮᱴᱟᱜ ᱯᱟᱦᱴᱟ ᱨᱮ ᱢᱮᱱᱟᱜ-ᱟ ᱾ ᱱᱚᱣᱟ ᱫᱚ ᱥᱟᱱᱟᱢ ᱫᱟᱲᱮ, ᱫᱟᱲᱮ ᱟᱨ ᱡᱚᱥ ᱠᱚ ᱞᱟᱹᱜᱤᱫ ᱢᱤᱫ ᱠᱮᱴᱮᱡ, ᱠᱮᱴᱮᱡ ᱦᱟᱹᱴᱤᱧ ᱠᱟᱱᱟ ᱾ ᱟᱢᱟᱜ ᱦᱚᱲᱢᱚ ᱨᱮ, ᱟᱢ ᱫᱚ ᱢᱟᱨᱟᱝ ᱮᱴᱠᱮᱴᱚᱬᱮ ᱟᱨ ᱚᱱᱟ ᱠᱚ ᱛᱟᱞᱟ ᱨᱮ ᱟᱢᱟᱜ ᱛᱤ ᱨᱮ ᱛᱟᱦᱮᱱ ᱠᱟᱛᱮ ᱜᱮ ᱾ ᱱᱚᱣᱟ ᱛᱮ ᱟᱢᱟᱜ ᱦᱟᱨᱛᱟ ᱫᱚ ᱟᱢᱟᱜ ᱦᱟᱨᱛᱟ, ᱡᱟᱝ, ᱟᱨ ᱟᱢᱟᱜ ᱡᱟᱝ, ᱟᱨ ᱡᱤᱞ ᱟᱨ ᱡᱟᱝ ᱨᱮᱭᱟᱜ ᱠᱮᱴᱮᱡ ᱟᱨ ᱠᱮᱴᱮᱡ ᱛᱮ ᱦᱩᱭᱩᱜ-ᱟ ᱾
ᱦᱟᱨᱛᱟ ᱨᱮᱭᱟᱜ ᱱᱟᱹᱢᱩ ᱞᱟᱹᱜᱤᱫ
ᱟᱢᱟᱜ ᱦᱚᱲᱢᱚ ᱨᱮ ᱟᱢᱟᱜ ᱦᱟᱨᱛᱟ, ᱜᱞᱩᱠᱚᱡᱽ, ᱟᱢᱟᱜ ᱦᱟᱨᱛᱟ, ᱟᱨ ᱟᱢᱟᱜ ᱦᱚᱲᱢᱚ ᱨᱮ ᱯᱮᱨᱤᱯᱷᱮᱨᱟᱞ ᱜᱞᱩᱠᱚᱡᱽ (Shime) ᱨᱮᱭᱟᱜ ᱱᱟᱹᱰᱨᱤ ᱨᱮᱭᱟᱜ ᱫᱟᱲᱮ ᱦᱚᱸ ᱢᱮᱱᱟᱜ-ᱟ ᱾ ᱡᱩᱫᱤ ᱟᱢᱟᱜ ᱦᱟᱨᱛᱟ ᱨᱮ ᱟᱭᱢᱟ ᱞᱮᱠᱟᱱ ᱡᱤᱞ ᱢᱮᱱᱟᱜᱼᱟ, ᱟᱨ ᱵᱟᱝ ᱠᱷᱟᱱ ᱟᱢᱟᱜ ᱦᱟᱨᱛᱟ, ᱢᱚᱥᱞᱟ, ᱟᱨ ᱵᱟᱝ ᱠᱷᱟᱱ ᱵᱟᱹᱲᱛᱤ, ᱟᱨ ᱦᱚᱸ᱾ ᱜᱤᱫᱽᱨᱟᱹ ᱠᱚ ᱫᱚ ᱠᱚᱞᱚᱱᱤ ᱠᱚ ᱥᱟᱶ ᱠᱚ ᱡᱚᱲᱟᱣ ᱟᱠᱟᱱᱟ ᱟᱨ ᱚᱱᱟ ᱠᱚ ᱫᱚ ᱵᱟᱝ ᱦᱩᱭᱩᱜ ᱠᱟᱱᱟ ᱟᱨ ᱚᱱᱟ ᱛᱮ ᱜᱞᱩᱠᱚᱡᱽ ᱟᱨ ᱠᱚᱯᱟᱨ ᱠᱚ ᱫᱚ ᱯᱤᱜᱽᱢᱮᱱᱴᱮᱥᱚᱱ ᱟᱨ ᱵᱟᱝ ᱛᱟᱦᱮᱱ ᱠᱚ ᱞᱟᱹᱜᱤᱫ ᱠᱚ ᱵᱟᱹᱲᱤᱡ ᱫᱟᱲᱮᱭᱟᱜ-ᱟ ᱾
ᱚᱡᱚᱱ ᱠᱚᱢ ᱞᱟᱹᱜᱤᱫ ᱟᱨ ᱯᱤ ᱟᱨ ᱯᱤ ᱟᱨ ᱡᱤᱞ ᱨᱮᱭᱟᱜ ᱮᱥᱮᱨ
ᱠᱮᱢᱤᱠᱮᱞ ᱟᱨ ᱡᱤᱞ ᱨᱮᱭᱟᱜ ᱡᱤᱞ ᱫᱚ ᱫᱚᱥᱟᱨ ᱜᱚᱲᱚ ᱛᱮ ᱜᱚᱲᱚ ᱫᱟᱲᱮᱭᱟᱜᱼᱟ ᱟᱨ ᱵᱟᱝ ᱵᱮᱥᱚᱜ ᱞᱟᱹᱜᱤᱫ ᱜᱚᱲᱚ ᱮᱢᱚᱜ ᱠᱟᱱᱟ᱾ ᱢᱮᱱᱠᱷᱟᱱ, HPVs (Chopposition, hyptosion) ᱫᱚ ᱢᱤᱫ ᱵᱟᱹᱲᱤᱡ ᱦᱚᱲ ᱞᱮᱠᱟ ᱵᱩᱡᱷᱟᱹᱣ ᱫᱟᱲᱮᱭᱟᱜ-ᱟ, ᱡᱟᱦᱟᱸ ᱫᱚ ᱜᱞᱩᱠᱚᱡᱽ ᱟᱨ ᱠᱚᱞᱚᱨᱮᱠᱴᱟᱞ ᱠᱮᱱᱥᱟᱨ ᱠᱚ ᱥᱟᱶ ᱡᱚᱲᱟᱣ ᱫᱟᱲᱮᱭᱟᱜ-ᱟ᱾
ᱩᱵ ᱞᱟᱹᱜᱤᱫ ᱯᱮᱨᱤᱯᱷᱮᱨᱟᱞᱟᱭᱡᱮᱥᱚᱱ ᱾
ᱛᱤᱱᱟᱹᱜ ᱜᱟᱱ ᱚᱠᱛᱚ ᱨᱮ ᱟᱢ ᱩᱵᱟᱨ, ᱦᱚᱲᱢᱚ ᱟᱨ ᱠᱮᱴᱮᱡ, ᱦᱚᱲᱢᱚ ᱨᱮᱭᱟᱜ ᱵᱟᱹᱲᱛᱤ ᱫᱟᱲᱮ ᱮᱢ ᱧᱟᱢ ᱫᱟᱲᱮᱭᱟᱜᱼᱟ᱾ ᱢᱤᱫ ᱫᱟᱹᱭᱠᱟᱹ ᱞᱮᱠᱟᱛᱮ, 1. gendiosphiphoptions ᱫᱚ ᱟᱹᱰᱤ ᱜᱟᱱ ᱦᱚᱲ ᱠᱚ ᱥᱟᱶ ᱥᱟᱶᱛᱮ ᱢᱮᱱᱟᱜ-ᱟ ᱡᱟᱦᱟᱸ ᱫᱚ ᱦᱚᱲᱢᱚ ᱨᱮ ᱵᱟᱹᱲᱛᱤ ᱦᱚᱲᱢᱚ ᱚᱡᱚᱱ ᱞᱮᱠᱟ ᱧᱮᱞᱚᱜ-ᱟ ᱾ ᱮᱴᱟᱜ ᱠᱚ ᱫᱚ ᱯᱞᱟᱴᱤᱱᱟᱢ ᱥᱮ ᱯᱮᱯᱴᱟᱭᱤᱰ ᱠᱚ ᱨᱮ ᱢᱤᱫ ᱥᱮ ᱯᱮᱯᱴᱟᱭᱤᱰ ᱠᱚ ᱵᱮᱵᱷᱟᱨ ᱠᱟᱛᱮ ᱟᱨ ᱵᱟᱝ ᱠᱷᱟᱱ ᱟᱢᱟᱜ ᱱᱟᱹᱢᱩᱱᱟ, ᱟᱨ ᱟᱢ ᱫᱚ ᱟᱢ ᱞᱟᱹᱜᱤᱫ ᱢᱤᱫ ᱱᱟᱹᱢᱩᱱᱟ ᱠᱚ ᱮᱢ ᱫᱟᱲᱮᱭᱟᱜ-ᱟ᱾
ᱡᱟᱝ ᱨᱮᱭᱟᱜ ᱡᱟᱝ ᱠᱚ ᱞᱟᱹᱜᱤᱫ
ᱟᱢᱟᱜ ᱡᱤᱞ ᱨᱮᱭᱟᱜ ᱡᱟᱝ ᱦᱚᱸ ᱟᱢᱟᱜ ᱦᱟᱨᱛᱟ ᱨᱮ ᱵᱟᱹᱲᱛᱤ ᱰᱟᱴᱟ ᱨᱮᱭᱟᱜ ᱰᱤᱜᱨᱮᱰᱮᱥᱚᱱ ᱦᱩᱭ ᱫᱟᱲᱮᱭᱟᱜᱼᱟ᱾ ᱢᱤᱫ ᱥᱮᱨᱢᱟ ᱛᱟᱭᱚᱢ, ᱜᱞᱩᱠᱚᱡᱽ (PD) ᱫᱚ ᱯᱮᱨᱤᱯᱷᱮᱨᱟᱞ ᱡᱟᱱᱟᱢ ᱠᱚ ᱨᱮ ᱵᱟᱹᱲᱛᱤ ᱵᱟᱹᱲᱛᱤ ᱢᱮᱱᱟᱜ-ᱟ ᱟᱨ ᱚᱱᱟ ᱛᱟᱭᱚᱢ ᱦᱚᱲᱢᱚ ᱨᱮ ᱡᱟᱱᱟᱢ ᱠᱟᱱ ᱡᱟᱱᱟᱢ ᱠᱚ ᱞᱟᱹᱜᱤᱫ ᱢᱤᱫ ᱢᱟᱨᱟᱝ ᱦᱤᱥ ᱠᱟᱱᱟ᱾
ᱯᱮᱯᱴᱟᱭᱤᱰ ᱨᱮᱭᱟᱜ ᱵᱤᱱᱤᱰ ᱞᱟᱹᱜᱤᱫ
ᱠᱷᱟᱥ ᱠᱟᱛᱮ (PH) ᱟᱨ hirginosion (phipplementions) ᱫᱚ ᱟᱢᱟᱜ ᱦᱚᱲᱢᱚ ᱨᱮ ᱵᱟᱝ ᱛᱟᱦᱮᱱ ᱠᱟᱱᱟ, ᱡᱟᱦᱟᱸ ᱫᱚ ᱜᱞᱩᱠᱚᱡᱽ (HTTP) ᱟᱨ ᱱᱭᱩᱠᱞᱤᱭᱟᱨ ᱨᱤᱥᱮᱯᱴᱚᱨ ( 15 ) ᱨᱮ ᱵᱟᱝ ᱛᱟᱦᱮᱱ ᱠᱟᱱᱟ ᱾ ᱱᱚᱶᱟ ᱯᱮᱨᱤᱯᱷᱮᱨᱟᱞ ᱦᱚᱨᱢᱚᱱ ᱫᱚ ᱟᱢᱟᱜ ᱦᱚᱨᱢᱚᱱ ᱨᱮᱭᱟᱜ ᱢᱤᱫ ᱥᱮᱬᱟ ᱦᱤᱥᱟᱹ ᱠᱟᱱᱟ ᱾
ᱪᱤᱠᱤᱥᱟ ᱟᱨ ᱛᱟᱭᱚᱢ ᱨᱮ ᱯᱟᱲᱦᱟᱣ ᱠᱚ
ᱩᱛᱱᱟᱹᱣᱤᱡ
PA ᱫᱚ ᱟᱡ ᱛᱮ ᱛᱟᱦᱮᱱ ᱠᱟᱱᱟ ᱟᱨ ᱠᱚᱢ ᱠᱷᱚᱱ ᱠᱚᱢ ᱵᱟᱹᱲᱛᱤ ᱦᱚᱲ ᱠᱚ ᱫᱚ ᱟᱠᱚᱣᱟᱜ ᱪᱤᱠᱤᱥᱟ ᱞᱟᱹᱜᱤᱫ ᱢᱤᱫ ᱞᱮᱠᱟᱱ ᱨᱟᱱ ᱠᱚ ᱨᱮᱭᱟᱜ ᱵᱟᱹᱲᱛᱤ ᱵᱟᱹᱲᱛᱤ ᱠᱚ ᱧᱟᱢ ᱫᱟᱲᱮᱭᱟᱜ-ᱟ ᱾ ᱚᱱᱟ ᱠᱚ ᱫᱚ ᱨᱚᱜᱽ ᱵᱟᱝᱠᱷᱟᱱ ᱠᱮᱱᱥᱟᱨ ᱨᱮᱭᱟᱜ ᱨᱚᱜᱽᱡᱚᱱᱤᱠ ᱨᱚᱜᱽ ᱥᱮ ᱚᱱᱟ ᱨᱮᱭᱟᱜ ᱠᱟᱨᱚᱱ, ᱥᱮ ᱮᱴᱟᱜ ᱨᱚᱜᱽ ᱠᱚ ᱩᱫᱩᱜ ᱫᱟᱲᱮᱭᱟᱜᱼᱟ᱾ ᱫᱟᱹᱭᱠᱟᱹ ᱞᱮᱠᱟᱛᱮ, 2.5 kg ᱫᱚ ᱢᱤᱫ ᱞᱮᱠᱟᱱ ᱪᱤᱠᱤᱥᱟᱱ ᱟᱨ ᱯᱞᱟᱡᱽᱢᱟ ᱨᱮᱭᱟᱜ ᱪᱤᱠᱤᱥᱟᱱ ᱠᱟᱱᱟ ᱡᱟᱦᱟᱸ ᱫᱚ ᱱᱤᱭᱚᱨᱚᱱ ᱨᱮᱭᱟᱜ ᱢᱮᱴᱟᱵᱚᱞᱤᱠ ᱵᱮᱵᱷᱟᱨ ᱠᱟᱱᱟ᱾
ᱰᱟᱭᱜᱽᱱᱚᱥᱴᱤᱠ ᱥᱟᱯᱟᱵ ᱠᱚ
ᱯᱤ ᱰᱤ ᱮᱥ ᱫᱚ ᱡᱟᱱᱣᱟᱨ ᱠᱚ ᱞᱟᱹᱜᱤᱫ ᱵᱮᱵᱷᱟᱨ ᱦᱩᱭ ᱫᱟᱲᱮᱭᱟᱜ-ᱟ ᱡᱟᱦᱟᱸ ᱫᱚ ᱱᱤᱭᱚᱨᱳᱯᱮᱛᱷᱚᱞᱚᱡᱤ ᱨᱮᱭᱟᱜ ᱵᱮᱵᱷᱟᱨ ᱦᱩᱭ ᱫᱟᱲᱮᱭᱟᱜ-ᱟ ᱾ ᱧᱮᱞ ᱡᱚᱛᱚᱱ ᱦᱚᱲ ᱠᱚ ᱫᱚ ᱮᱴᱟᱜ ᱮᱴᱟᱜ ᱠᱚ ᱨᱮ ᱵᱟᱝ ᱛᱟᱦᱮᱱ ᱟᱨ ᱵᱟᱝ ᱛᱟᱦᱮᱱ ᱠᱚ ᱧᱮᱞ ᱫᱟᱲᱮᱭᱟᱜ-ᱟ, ᱟᱨ ᱵᱟᱝ ᱠᱷᱟᱱ ᱠᱚᱞᱚᱨᱮᱠᱴᱟᱞ ᱠᱚ ᱫᱚ ᱵᱟᱝ ᱵᱟᱰᱟᱭ ᱠᱚ ᱧᱟᱢ ᱫᱟᱲᱮᱭᱟᱜ-ᱟ ᱾
ᱱᱤᱭᱳᱨᱳᱥᱤᱥ
PAID ᱫᱚ ᱵᱟᱭᱚᱴᱮᱠᱱᱚᱞᱚᱡᱤ ᱨᱮᱭᱟᱜ ᱵᱮᱵᱷᱟᱨ ᱠᱟᱱᱟ, ᱠᱷᱟᱥ ᱠᱟᱛᱮ ᱵᱟᱭᱚᱯᱷᱤᱞᱢ ᱟᱨ ᱤᱱᱡᱮᱠᱥᱚᱱ ᱠᱚ ᱨᱮᱭᱟᱜ ᱯᱟᱥᱱᱟᱣ ᱞᱟᱹᱜᱤᱫ ᱾ ᱩᱱᱠᱩᱣᱟᱜ ᱫᱟᱲᱮ ᱟᱨ ᱵᱮᱵᱷᱟᱨ ᱠᱚ ᱫᱚ ᱟᱠᱚᱣᱟᱜ ᱡᱚᱥ ᱟᱨ ᱵᱮᱵᱷᱟᱨ ᱠᱚ ᱞᱟᱹᱜᱤᱫ ᱟᱠᱚᱣᱟᱜ ᱫᱟᱲᱮ ᱨᱮᱭᱟᱜ ᱪᱤᱱᱦᱟᱹ ᱠᱚ ᱵᱟᱰᱟᱭ ᱞᱟᱹᱜᱤᱫ ᱠᱚ ᱩᱫᱽᱜᱟᱹᱣ ᱮᱫᱟ᱾
ᱠᱟᱜᱚᱡᱽ ᱟᱨ ᱯᱷᱤᱴᱤᱝ ᱞᱟᱹᱜᱤᱫ ᱟᱞᱜᱟ ᱛᱮ ᱛᱟᱲᱟᱢ ᱢᱮ ᱾
ᱡᱤᱱᱤᱥ ᱠᱚ ᱫᱚ ᱚᱠᱛᱚ ᱥᱟᱶ ᱥᱟᱶ ᱛᱮ ᱵᱟᱝ ᱵᱮᱵᱷᱟᱨᱚᱜᱼᱟ ᱛᱤᱱ ᱦᱟᱹᱵᱤᱡ ᱚᱱᱟ ᱫᱚ ᱵᱟᱝ ᱵᱮᱥᱚᱜᱼᱟ ᱾
2000-2000 ᱨᱮ −2.2 ᱨᱮ, ᱟᱞᱮ ᱫᱚ 1D (meaning lạgit̕ jạruṛa ) ᱨᱮ ᱵᱟᱹᱲᱛᱤ ᱞᱮ ᱠᱷᱚᱨᱚᱪ ᱠᱮᱫᱟ – ᱟᱨ ᱚᱱᱟ ᱫᱚ https://teption-mode lạgit̕ lạgit̕ lạgit̕ lạgit̕ lạgit̕ lạgit̕ lạgit̕ lạgit̕ lạgit̕ lạgit̕ lạgit̕ lạgit. ᱱᱚᱣᱟ ᱫᱚ ᱥᱟᱨᱟ ᱜᱷᱟᱹᱲᱤᱡ ᱜᱮ ᱢᱟᱨᱥᱟᱞ ᱠᱷᱚᱱ ᱥᱟᱦᱟᱨᱮ ᱛᱟᱦᱮᱱ ᱞᱟᱹᱜᱤᱫ ᱵᱮᱥ ᱜᱮᱭᱟ ᱾
ᱢᱟᱨᱟᱝ ᱱᱳᱰ ᱠᱚ ᱫᱚ https lg.com } _________________________________ ᱾ ᱵᱮᱵᱷᱟᱨ ᱢᱟᱲᱟᱝ ᱨᱮ, ᱫᱟᱜ ᱟᱨ ᱱᱟᱹᱢᱩᱱᱟ ᱠᱚ ᱚᱪᱚᱜ ᱞᱟᱹᱜᱤᱫ ᱜᱞᱩᱠᱚᱡᱽ ᱫᱚ ᱢᱟᱲᱟᱝ ᱠᱷᱚᱱ ᱜᱮ ᱵᱮᱵᱷᱟᱨ ᱠᱟᱛᱮ ᱫᱚᱦᱚ ᱞᱟᱹᱜᱤᱫ ᱱᱟᱹᱢᱩᱱᱟ ᱠᱚ ᱫᱚᱦᱚ ᱠᱟᱜ-ᱟ ᱾ ᱱᱚᱣᱟ ᱫᱚ ᱱᱚᱣᱟ ᱠᱚ ᱢᱩᱫᱽ ᱨᱮ ᱢᱤᱫ ᱴᱟᱝ ᱠᱟᱱᱟ ᱡᱟᱦᱟᱸ ᱫᱚ ᱦᱚᱭ ᱦᱤᱥᱤᱫ ᱨᱮ ᱠᱚᱢᱡᱩᱨᱤ ᱠᱚ ᱨᱮ ᱴᱮᱦᱟᱱᱰ ᱢᱮᱱᱟᱜᱼᱟ ᱾
ᱱᱟᱹᱢᱩᱱᱟ ᱠᱚ ᱫᱚ 0.4 ± SEM ᱠᱷᱚᱱ ᱧᱟᱢ ᱟᱠᱟᱱ ᱱᱟᱹᱢᱩᱱᱟ ᱠᱷᱚᱱ ᱧᱟᱢ ᱟᱠᱟᱱᱟ ᱡᱟᱦᱟᱸ ᱫᱚ ᱱᱟᱹᱢᱩᱱᱟ ᱟᱨ ᱯᱟᱨᱤᱵᱮᱥ ᱠᱷᱚᱱ ᱟᱞᱜᱟ ᱜᱮᱭᱟ ᱾ ᱡᱩᱫᱤ ᱢᱤᱫ ᱥᱮ ᱵᱟᱹᱲᱛᱤ ᱚᱠᱛᱚ ᱞᱟᱜᱟᱣ ᱠᱷᱟᱱ ᱥᱮ ᱵᱟᱹᱲᱛᱤ ᱠᱟᱹᱢᱤ ᱠᱷᱚᱱ ᱥᱟᱦᱟᱜ ᱞᱟᱹᱜᱤᱫ, ᱥᱴᱚᱠ ᱫᱚ ᱢᱟᱲᱟᱝ ᱠᱷᱚᱱ ᱜᱮ ᱠᱟᱹᱢᱤ ᱞᱟᱹᱜᱤᱫ ᱢᱤᱫ ᱴᱷᱟᱶ ᱨᱮ ᱫᱚᱦᱚ ᱠᱟᱜ-ᱟ ᱾
In general, peptide solutions are stable for up to a week at 4 °C. However, if the peptide sequence has inherent instability, it might be better to freeze the solution when not in use. Peptide solutions at pH>᱘. ᱵᱮᱵᱷᱟᱨ ᱞᱟᱹᱜᱤᱫ ᱦᱚᱸ ᱱᱚᱣᱟ ᱫᱚ ᱵᱟᱝ ᱦᱩᱭᱩᱜ ᱞᱟᱹᱠᱛᱤ ᱾
ᱡᱤᱭᱚᱱ ᱨᱮᱭᱟᱜ ᱢᱤᱫ ᱦᱟᱹᱴᱤᱧ ᱫᱚ ᱦᱩᱭᱩᱜ ᱠᱟᱱᱟ᱾ QTL, CO, ᱟᱨ COPD ᱨᱮ, ᱡᱟᱦᱟᱸ ᱫᱚ ᱱᱟᱹᱢᱩᱱᱟ ᱠᱚ ᱨᱮ ᱪᱮᱫ ᱦᱚᱸ ᱵᱟᱝ ᱵᱮᱵᱷᱟᱨᱚᱜᱼᱟ ᱾ ᱯᱷᱨᱤᱠᱩᱣᱮᱱᱥᱤ (᱖-᱕) ᱫᱚ ᱯᱷᱨᱤᱠᱩᱣᱮᱱᱥᱤ ᱟᱨ ᱮᱴᱟᱜ ᱡᱤᱱᱤᱥ ᱠᱚ ᱨᱮᱭᱟᱜ ᱵᱮᱵᱷᱟᱨ ᱠᱟᱛᱮ ᱯᱷᱨᱤᱠᱩᱣᱮᱱᱥᱤ ᱨᱮ ᱫᱚᱦᱚ ᱞᱟᱹᱜᱤᱫ ᱵᱮᱵᱷᱟᱨᱚᱜ ᱠᱟᱱᱟ ᱾ ᱒᱐-ᱢᱤᱢᱤᱴᱚᱨ ᱵᱟᱝᱠᱷᱟᱱ ᱵᱟᱹᱲᱛᱤ ᱞᱚᱞᱚ ᱫᱚ ᱨᱮᱭᱟᱲ ᱜᱮᱭᱟ ᱾
The most effective way to prevent or minimize peptide degradation is to store the peptide in lyophilized/powder form at –20 °C or preferably at –80 °C. If the peptide is in solution, freeze thaw cycles should be avoided by freezing individual aliquots. Exposure to pH>8 should be avoided. However, if it is necessary to dissolve peptides at pH>᱘, ᱥᱚᱢᱟᱫᱷᱟᱱ ᱠᱚ ᱫᱚ ᱴᱷᱟᱹᱣᱠᱟᱹ ᱜᱮᱭᱟ ᱾ ᱢᱩᱪᱟᱹᱫ ᱨᱮ, ᱜᱞᱩᱠᱚᱡᱽ ᱟᱨ ᱜᱞᱩᱠᱚᱡᱽ (ᱯᱤ ᱰᱤ) ᱫᱚ ᱵᱟᱹᱲᱛᱤ ᱵᱟᱹᱲᱛᱤ ᱵᱟᱹᱲᱛᱤ ᱵᱟᱹᱲᱛᱤ ᱵᱟᱹᱲᱛᱤ ᱵᱟᱹᱲᱛᱤ ᱠᱟᱱᱟ ᱟᱨ ᱚᱱᱟ ᱨᱮᱭᱟᱜ ᱠᱟᱹᱢᱤ ᱫᱚ ᱜᱞᱩᱠᱚᱡᱽ ᱨᱮ ᱫᱚᱦᱚ ᱠᱟᱱᱟ᱾
ᱵᱮᱵᱷᱟᱨ ᱢᱮ ᱟᱨ ᱵᱤᱱᱤᱰ ᱢᱮ
ᱵᱷᱤᱠᱴᱚᱨ
ᱤᱣᱱᱤᱴ
ᱟᱵᱚ ᱫᱚ ᱢᱤᱫ ᱞᱮᱠᱟᱱ ᱟᱨᱟᱵᱽ ᱵᱚᱱ ᱧᱟᱢ ᱮᱫᱟ ᱡᱟᱦᱟᱸ ᱫᱚ ᱮᱴᱟᱜ ᱗᱕ ᱟᱨᱟᱵᱽ ᱟᱨ ᱮᱴᱟᱜ ᱜᱷᱟᱨᱚᱧᱡᱽ ᱠᱚ ᱥᱟᱶ ᱡᱚᱲᱟᱣ ᱢᱮᱱᱟᱜ-ᱟ ᱾ ᱫᱟᱭᱟ ᱠᱟᱛᱮ ᱟᱞᱮᱭᱟᱜ ᱮᱴᱟᱜ ᱠᱷᱮᱢᱚᱛᱟ ᱠᱤᱨᱤᱧ ᱞᱟᱹᱜᱤᱫ ᱱᱚᱸᱰᱮ ᱠᱷᱚᱱ ᱵᱟᱹᱲᱛᱤ ᱜᱚᱱᱚᱝ ᱞᱟᱹᱜᱤᱫ ᱟᱞᱮᱭᱟᱜ ᱯᱷᱨᱤᱠᱣᱮᱱᱥᱤ ᱞᱮ ᱮᱢᱚᱜ ᱠᱟᱱᱟ ᱾ ᱡᱤᱱᱤᱥ ᱠᱚ ᱫᱚ ᱠᱚᱢ ᱜᱮᱭᱟ ᱟᱨ ᱜᱚᱱᱚᱝ ᱫᱚ ᱠᱚᱢ ᱜᱮᱭᱟ ᱾